# A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

> **NCT05658458** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 205 (actual)

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction
- Worsening Heart Failure

## Interventions

- **DRUG:** Vericiguat (Verquvo, BAY1021189)

## Key facts

- **NCT ID:** NCT05658458
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-16
- **Primary completion:** 2024-09-19
- **Final completion:** 2024-09-19
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05658458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05658458, "A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05658458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*